Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 17 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				CCBX001-049 NCT00078598


2.		Comparative Trial Between Bexxar and Zevalin

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Approved-not yet active				18 and over				Pharmaceutical / Industry				CCBX001-053 NCT00078676


3.		Comparison of Rituxan Versus Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (ASCT)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 80				NHLBI				384 BMT CTN 0401, U01 HL069294-05, NCT00329030


4.		Comparison of Rituxan Versus Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (ASCT)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 80				NCI, NHLBI				384 BMT CTN 0401, U01 HL069294-05, NCT00329030


5.		Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				J0703 NA00005743, NCT00484874

Last Modified: 11/14/2007 First Published: 11/20/2003


6.		Phase II Study of Iodine I 131 Tositumomab, Etoposide, and Cyclophosphamide Followed By Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 to 59				NCI				FHCRC-1368.00 NCT00073918

Last Modified: 10/4/2008 First Published: 3/24/2005


7.		Phase II Study of Iodine I 131 Tositumomab in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Older Patients With Previously Untreated Bulky Stage II or Stage III or IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				SWOG-S0433 NCT00107380, S0433


8.		Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				UMCC 2005.035 NCT00135200


9.		Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				GSK Protocol #109407 NCT00475332


10.		Study Looking to See How Effective Fludarabine and Rituximab Followed by Bexxar Are for CLL or SLL

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				PSOC 2301 NCT00476047

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute